Healthcare -
Biotechnology - NASDAQ - US
$ 14.52
-6.02 %
$ 1.1 B
Market Cap
-5.04
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Nurix Therapeutics, Inc.
| Revenue | 54.5 M |
| Cost Of Revenue | 0 |
| Gross Profit | 54.5 M |
| Operating Expenses | 268 M |
| Operating Income | -213 M |
| Other Expenses | -19.5 M |
| Net Income | -194 M |
Income Statement
Millions
| Nov-2024 | Nov-2023 | Nov-2022 | Nov-2021 | Nov-2020 | Nov-2019 | Nov-2018 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 54.5 | 77.0 | 38.6 | 29.8 | 17.8 | 31.1 | 37.4 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 0 | 189.1 | 10.8 | 6.1 | 66.5 | 45.0 | 40.5 |
| Gross Profit | 54.5 | (112.2) | 27.8 | 23.7 | (48.7) | (13.9) | (3.1) |
| OPERATING INCOME | |||||||
| Operating Expenses | 267.6 | 232.1 | 222.5 | 147.6 | 82.8 | 53.4 | 47.2 |
| Selling, General and Administrative Expenses | 45.9 | 42.9 | 38.0 | 31.2 | 16.3 | 8.3 | 6.7 |
| Research and Development Expenses | 221.6 | 189.1 | 184.5 | 116.4 | 66.5 | 45.0 | 40.5 |
| Operating Income | (213.0) | (155.1) | (183.9) | (117.9) | (65.0) | (22.2) | (9.7) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 19.7 | 11.1 | 3.5 | 0.8 | 1.2 | 0.8 | 0.8 |
| Pre-Tax Income | (193.3) | (143.9) | (180.4) | (117.1) | (63.8) | (21.5) | (8.9) |
| NET INCOME | |||||||
| Tax Provision | 0.3 | 0 | (14.3) | 0.1 | (20.5) | 0.2 | 0.5 |
| Net Income | (193.6) | (143.9) | (166.0) | (117.2) | (43.2) | (21.7) | (9.4) |
| EPS | 2.88 | 2.65 | 3.42 | 2.73 | 2.76 | 0.56 | 0.59 |